Modulated Electrohyperthermia with Dose-Dense Temozolomide for Recurrent Glioblastoma
Modulated Electrohyperthermia with Dose-Dense Temozolomide for Recurrent Glioblastoma
Recurrent glioblastoma remains one of the most difficult cancers to treat, with limited therapeutic options once the disease progresses after initial therapy. Roussakow conducted a retrospective analysis examining the outcomes of patients with recurrent glioblastoma who received dose-dense temozolomide chemotherapy with or without the addition of modulated electrohyperthermia.
This two-centre German cohort study evaluated patients treated with a dose-dense temozolomide schedule administered 21 days out of a 28-day cycle. Some patients received chemotherapy alone, while others received chemotherapy combined with modulated electrohyperthermia, a treatment that uses radiofrequency energy to heat tumor tissues with the aim of enhancing the effects of chemotherapy and promoting tumor cell stress.
The analysis suggested that patients receiving the combined treatment experienced improved clinical outcomes compared with those receiving temozolomide alone. The addition of electrohyperthermia was associated with longer overall survival and better treatment response, supporting the hypothesis that targeted thermal therapy may enhance the effectiveness of chemotherapy in aggressive brain tumors.
While this retrospective analysis cannot establish definitive causation, the findings contribute to a growing body of research exploring hyperthermia-based therapies as adjuncts to standard cancer treatments. The results suggest that combining modulated electrohyperthermia with chemotherapy may offer potential benefits for patients with recurrent glioblastoma and warrant further investigation in prospective clinical trials.
Reference:
Roussakow SV. Clinical and economic evaluation of modulated electrohyperthermia concurrent to dose-dense temozolomide 21/28 days regimen in the treatment of recurrent glioblastoma: a retrospective analysis of a two-centre German cohort trial with systematic comparison and effect-to-treatment analysis. BMJ Open. 2017;7(11):e017387. doi:10.1136/bmjopen-2017-017387. PMID: 29102988.
